Your browser doesn't support javascript.
loading
Factors affecting bone mineral density in children and adolescents with secondary osteoporosis.
Jang, Min Jeong; Shin, Chungwoo; Kim, Seongkoo; Lee, Jae Wook; Chung, Nack-Gyun; Cho, Bin; Jung, Min Ho; Suh, Byung-Kyu; Ahn, Moon Bae.
Afiliação
  • Jang MJ; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Shin C; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim S; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Lee JW; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Chung NG; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Cho B; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Jung MH; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Suh BK; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Ahn MB; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ann Pediatr Endocrinol Metab ; 28(1): 34-41, 2023 Mar.
Article em En | MEDLINE | ID: mdl-35798303
ABSTRACT

PURPOSE:

This study aimed to investigate the clinical factors associated with bone mineral density (BMD) among children and adolescents with osteoporosis secondary to treatment for underlying clinical conditions.

METHODS:

We retrospectively reviewed the medical records of patients aged 10-18 years and evaluated them for lumbar spine BMD (LSBMD) after treatment for underlying diseases, including hemato-oncologic, rheumatologic system, and inflammator y bowel diseases. LSBMD measured by dual-energy x-ray absorptiometry (DXA) performed from March 2019 to March 2021 was evaluated. We analyzed 117 patients who underwent initial DXA after treatment for underlying diseases.

RESULTS:

Subjects in this study had multiple underlying diseases hemato-oncologic (78.6%), rheumatologic (11.1%), and inflammatory bowel diseases (10.3%). There was no significant association between the z-score and bone metabolic markers (P>0.05). However, higher cumulative glucocorticoid (GC) dose significantly reduced LSBMD z-score (P=0.029). Moreover, the association between cumulative dose of GC and initial z-score of LSBMD was significant in logarithmic regression analysis (P=0.003, R2=0.149). GC accumulation was a significant risk factor for vertebral fracture when the initial BMD was evaluated after treatment (P=0.043). Bone metabolic markers did not significantly influence the risk of vertebral fracture.

CONCLUSION:

Initial bone mass density of the lumbar spine evaluated after long-term GC use for underlying diseases is a predictor of further vertebral fractures.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Pediatr Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Pediatr Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article